New Pain Medicine Approved
This is a news story, published by Good News Network, that relates primarily to Journavx news.
Journavx news
For more Journavx news, you can click here:
more Journavx newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsGood News Network news
For more news from Good News Network, you can click here:
more news from Good News NetworkAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
pain medicine. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest acute pain management news, analgesic news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
pain signal inhibitorGood News Network
•Health
Health
FDA Approves Opioid-free Pain Medication That Finally Delivers Relief Without Addiction

72% Informative
The FDA has approved the first drug in its class that targets moderate to severe acute pain in adults without being addictive like opioids.
Vertex Pharmaceuticals is set to sell the twice daily pills for $ 15 per dose under the name Journavx .
The most common adverse reactions in patients were itching, muscle spasms, increased blood level of creatine phosphokinase.
VR Score
57
Informative language
47
Neutral language
68
Article tone
formal
Language
English
Language complexity
61
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
6
Source diversity
3
Affiliate links
no affiliate links